About Catalent Pharma Solutions
Catalent's story began in 2007, emerging as a pivotal force in the pharmaceutical, biotechnology, and consumer health industries. However, its rich legacy in drug development stretches back much further, to 1933, with R.P. Scherer's groundbreaking invention of the rotary die process for softgel encapsulation. This innovation transformed softgel production from a manual art into a high-volume commercial process, laying the foundation for what would become a global leader in drug delivery. Over the decades, the company, through various evolutions, consistently pushed the boundaries of pharmaceutical science. Key milestones include the development of Zydis®, a pioneering fast-dissolving oral dosage form in 1982, and the acquisition of GPEx® gene-insertion technology in 2003, significantly expanding its capabilities in biologic drug manufacturing. These innovations underscore a continuous commitment to advancing how medicines are developed and delivered to patients.
The formal establishment of Catalent in 2007 marked a new chapter, consolidating a wealth of experience and expertise under a single banner. The name itself, a blend of 'Catalyst' and 'Talent,' reflects its core mission: to be the spark that enables its partners' success through the skill and dedication of its people. In July 2014, Catalent took a significant step by becoming a publicly traded company on the New York Stock Exchange, further fueling its growth and expansion. Throughout its journey, Catalent has strategically acquired companies and technologies to broaden its service offerings, including particle size engineering, spray drying capabilities, and expertise in cell and gene therapy. The company played a crucial role during the COVID-19 pandemic, partnering with major pharmaceutical companies to manufacture and package vaccines. In a landmark development, Novo Holdings A/S completed its acquisition of Catalent in December 2024, ushering in a new era for the company as it continues its mission to develop, manufacture, and supply products that help people live better, healthier lives across the globe.
FAQs
- When was Catalent Pharma Solutions founded?
- Catalent Pharma Solutions was founded in 2007.
- Who is the CEO of Catalent Pharma Solutions?
- Alessandro Maselli is the CEO.
- What industries or markets does Catalent Pharma Solutions operate in?
- Catalent Pharma Solutions operates in the following markets: Biotechnology, Drug Delivery Systems, Contract Development and Manufacturing Organization (CDMO), Vaccine Manufacturing, Healthcare Services, Pharmaceuticals, Biologic Drug Manufacturing, Consumer Health, Oral Drug Delivery, Gene and Cell Therapy, and Pharmaceutical.
- How many employees does Catalent Pharma Solutions have?
- Catalent Pharma Solutions has 5000+ employees.
- Where does Catalent Pharma Solutions have employees?
- Catalent Pharma Solutions has employees in United States.
- Does Catalent Pharma Solutions support remote work or working from home?
- Yes, Catalent Pharma Solutions is a remote-friendly company.
- What employee benefits does Catalent Pharma Solutions offer?
- Catalent Pharma Solutions provides 16 benefits to their employees.
- Does Catalent Pharma Solutions offer a four-day work week?
- No, Catalent Pharma Solutions does not offer a four-day work week.
- What is Catalent Pharma Solutions's tech stack?
- Catalent Pharma Solutions has 4 technologies in their tech stack.
- What is Catalent Pharma Solutions's website?
- Catalent Pharma Solutions's website is www.catalent.com.